ProCE Banner Activity

MajesTEC-1 Update: Phase I/II Study of Teclistamab in Patients With R/R MM

Conference Coverage
Slideset

With a median follow-up of approximately 2 years, teclistamab continued to show deep and durable responses in patients with triple- or penta-class refractory MM, with improved safety following switching to less frequent dosing.

Released: June 09, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AbbVie, Geron, Jazz Pharmaceuticals, Lilly, Merck Sharp & Dohme Corp., and Novartis.

AbbVie

Geron

Jazz Pharmaceuticals

Lilly

Merck Sharp & Dohme Corp.

Novartis